--iTeos Therapeutics and GlaxoSmithKline plc today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a ...

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...

Shares of iTeos Therapeutics Inc. soared 58.5% in premarket trading on Monday after the company announced a deal with GlaxoSmithKline to develop and commercialize an experimental cancer therapy.

iTeos is the latest, but perhaps most high-profile casualty, of a faltering anti-TIGIT landscape. Until this point, only drug candidates had primarily been lost, as opposed to entire biotechs.

WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...

Turning to iTeos Therapeutics' balance sheet, the company had cash and cash equivalents of $216.2M, short-term investments of $383.0M, and long-term investments of $78.3M as of June 30, 2023.

--iTeos Therapeutics, Inc. today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC will acquire iTeos for $10.047 in cash per share of iTeos ...

“As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we’re excited to welcome Dr. Feltquate as Chief Medical Officer,” said Michel ...

Based on the results, iTeos and GSK are stopping all ongoing trials of belrestotug, including an ongoing Phase 3 study in lung cancer. iTeos is “taking immediate steps to preserve capital” as ...

WATERTOWN, Mass. and GOSSELIES, Belgium, May 10, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a ...